2026-10-20 14:34:22 UTC#487131newconfirmednews
OCUL stock news
OCUL stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire11 wire items
2026-10-19 17:21:00 UTC#482074newconfirmednews
Needham maintains $18.00 price target on Ocular Therapeutix (OCUL)
2026-10-16 20:23:01 UTC#473971newconfirmednews
Ocular Therapeutix Chief Strategy Officer Sanjay Nayak resigns effective October 16, 2026
2026-10-12 13:30:00 UTC#446908newconfirmednews
UBS initiates Ocular Therapeutix (OCUL) at Buy with $14.00 price target
2026-09-29 09:56:00 UTC#383048newconfirmednews
Needham maintains $18.00 price target on Ocular Therapeutix (OCUL)
2026-09-16 10:24:49 UTC#319810newconfirmednews
HC Wainwright & Co. reiterates Buy rating on Ocular Therapeutix, maintains $25 price target
tradingview_analyst_updatesimportance 0.30trust 0.70HC Wainwright & Co. +0.30Ocular Therapeutix, Inc. +0.40Dextenza +0.20+1 entities
2026-09-15 16:21:11 UTC#315409newconfirmednews
Ocular Therapeutix (OCUL) targets 2027 AXPAXLI launch following positive SOL-1 data and FDA alignment
2026-09-15 16:02:16 UTC#315252newconfirmednews
Ocular Therapeutix (OCUL) targets Q4 2024 NDA filing for wet AMD therapy SOL-1 after positive trial data
quartrimportance 0.60trust 0.60Ocular Therapeutix, Inc. +0.60Aflibercept -0.30SOL-1 +0.60+1 entities
2026-08-03 11:07:48 UTC#116139newconfirmednews
Ocular Therapeutix Q2 GAAP EPS -$0.35 beats by $0.04, Revenue $13.48M beats by $0.28M
2026-07-22 23:18:05 UTC#66295newconfirmednews
Ocular Therapeutix (OCUL) to file NDA for AXPAXLI in Q4 following FDA alignment on trial data
quartrimportance 0.60trust 0.60Ocular Therapeutix, Inc. +0.60AXPAXLI +0.60Food and Drug Administration +0.40
2026-07-22 13:26:27 UTC#63206newconfirmedanalysis